intermediate-stage hepatocellular carcinoma
Conditions
Brief summary
Time to failure of treatment strategy (TTFS)
Detailed description
Overall Survival (OS), Overall Survival Rate at 24 months (OS@24), Objective Response Rate (ORR), Time to Progression (TTP), Time to loss of systemic treatment options (TTSYS), Progression free survival (PFS), Duration of Treatment, Duration of Response (DOR), Time to deterioration of liver function, Safety, QoL (Patient Reported Outcome; PRO), Baseline PD-L1 protein expression in FFPE tumor tissue
Interventions
DRUGTecentriq 1 200 mg concentrate for solution for infusion
DRUGAvastin 25 mg/ml concentrate for solution for infusion.
Sponsors
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to failure of treatment strategy (TTFS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS), Overall Survival Rate at 24 months (OS@24), Objective Response Rate (ORR), Time to Progression (TTP), Time to loss of systemic treatment options (TTSYS), Progression free survival (PFS), Duration of Treatment, Duration of Response (DOR), Time to deterioration of liver function, Safety, QoL (Patient Reported Outcome; PRO), Baseline PD-L1 protein expression in FFPE tumor tissue | — |
Countries
Austria, France, Germany, Italy, Spain
Outcome results
None listed